Paul Carter

Paul Carter is a seasoned international BioPharma leader with an outstanding and proven track record. He has over 25 years of senior executive experience, specializing in commercialization, regional leadership, and mergers and acquisitions. Mr. Carter is currently a Board Director and Committee Chair of four US-listed BioPharma companies HutchMed PLC, Mallinckrodt Pharmaceuticals, Immatics NV, and VectivBio Inc.

Prior to this, Mr. Carter served as Executive Vice-President and Chief Commercial Officer of Gilead Sciences Inc., where he was responsible for the company’s worldwide commercial activity, including $33 billion of revenue in 2015 and launching several of the biggest selling prescription drugs of all time. Before that Paul had senior leadership roles in GSK (and its legacy companies), including head of GSK China and head of Smith Kline Beecham Russia. He has lived and worked extensively in the US, Europe, and Asia and continues to be strongly networked and professionally connected to a diverse range of publicly listed and private life science-orientated businesses in these territories.